LONDON — A new non-invasive imaging agent has shown there can be unexpected changes in human epidermal growth factor receptor type 2 (HER2) status from primary breast cancer to metastatic disease, and that as a result some women are inappropriately being treated with HER2 positive-targeted drugs.